Stephan Michels
About
In The Last Decade
Stephan Michels
115 papers receiving 4.9k citations
Hit Papers
Peers
Comparison fields: 5 of 93
- Ophthalmology 4.6k
- Radiology, Nuclear Medicine and Imaging 3.1k
- Molecular Biology 663
- Biomedical Engineering 538
- Pulmonary and Respiratory Medicine 233
Countries citing papers authored by Stephan Michels
This map shows the geographic impact of Stephan Michels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Michels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Michels more than expected).
Fields of papers citing papers by Stephan Michels
This network shows the impact of papers produced by Stephan Michels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Michels. The network helps show where Stephan Michels may publish in the future.
Co-authorship network of co-authors of Stephan Michels
This figure shows the co-authorship network connecting the top 25 collaborators of Stephan Michels. A scholar is included among the top collaborators of Stephan Michels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephan Michels. Stephan Michels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 8 | |
| 2 | 2 | |
| 3 | 9 | |
| 4 | 2 | |
| 5 | 200 | |
| 6 | 81 | |
| 7 | A Swiss Patient Cohort Reveals Genetic Predisposition Of Known And New Genetic Loci To AMD And To Intravitreal Ranibizumab (lucentis®) Treatment Outcome | 2 |
| 8 | Comparison of Reduced Fluence versus Standard Fluence Verteporfin Therapy in Combination With Intravitreal Triamcinolone Acetonide: A Prospective, Randomized, Controlled Clinical Trial | 1 |
| 9 | An OCT-Guided Variable-Dosing Regimen With Ranibizumab (Lucentis) in Neovascular AMD: Two Year Results of the PrONTO Study | 2 |
| 10 | Characteristics of Patients Losing Vision at Year 1 of the PrONTO Study | 1 |
| 11 | Changes in Functional Macular Mapping in Patients With Neovascular Age–Related Macular Degeneration Receiving Combination of Verteporfin (Visudyne®) and Ranibizumab (LucentisTM) Therapy | 2 |
| 12 | Visual Acuity Outcomes Following a Variable–Dosing Regimen for Ranibizumab (LucentisTM) in Neovascular AMD: The PrONTO Study | 11 |
| 13 | Vascular Effects of Combined Ranibizumab (Lucentis®) and Verteporfin (Visudyne®) Therapy in Patients With Neovascular Age–Related Macular Degeneration | 2 |
| 14 | VEGF 165 Serum Levels Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration | 1 |
| 15 | Thickness Mapping of Photoreceptors of the Foveal Region in Normals Using Three–Dimensional Optical Coherence Tomography | 3 |
| 16 | Retinal Vasculature Imaging Using Three Dimensional Ultra–High Resolution Optical Coherence Tomography | 1 |
| 17 | Three–Dimensional Ultrahigh Resolution Optical Coherence Tomography (3D UHR OCT): A Video Presentation | 1 |
| 18 | Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration (SANA) Study: Visual Acuity Outcomes | 0 |
| 19 | Characteristic Findings in Stratus OCT in Patients With Predominantly Occult Choroidal Neovascularization (CNV) in Age–Related Macular Degeneration Treated With Verteporfin Therapy and Intravitreal Triamcinolone | 1 |
| 20 | Imaging of Pigment Epithelial Disease Using Threedimensional (3D) Ultrahigh Resolution (UHR) Optical Coherence Tomography (OCT) | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.